Myelodysplastic Syndrome With Excess Blasts-2 (MDS-EB-2) Terminated Phase 2 Trials for Cytarabine (DB00987)

Also known as: Myelodysplastic Syndrome With Excess Blasts-2

IndicationStatusPhase
DBCOND0092771 (Myelodysplastic Syndrome With Excess Blasts-2 (MDS-EB-2))Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04526288CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual DiseaseTreatment